PAS, CBE-30 or Annual Report: Choosing a Reporting Category

Quality proposes a change to an approved product. A new drug substance site, a different supplier for a component, a modified process step. Regulatory then has to answer one question: how do we report this, and when can we implement it?

For an NDA or ANDA, 21 CFR 314.70 gives three answers, and the choice is worth months.

The three routes

Prior Approval Supplement (PAS). For changes with a substantial potential to have an adverse effect on identity, strength, quality, purity or potency. You file, and you wait for FDA to approve before distributing product made with the change. Budget on the order of months.

Changes Being Effected in 30 Days (CBE-30). For moderate changes. You file, and if FDA does not object within 30 days you may distribute. A plain CBE without the 30 days exists for a narrower set of changes and permits immediate distribution.

Annual Report. For minor changes with minimal potential for an adverse effect. You implement now and describe it in the next annual report.

Biologics run on the parallel structure in 21 CFR 601.12, which uses the same three tiers.

Over-reporting is a real cost

The instinct under uncertainty is to file the higher category, because nobody gets criticised for being conservative. That instinct is expensive.

A change filed as a PAS that belonged in an annual report costs you the FDA review clock you did not need to wait out, plus the review resource, plus the delay to whatever the change was meant to achieve. A CBE-30 for something an annual report would have covered costs a filing and a 30 day wait.

This happens constantly. The reflex is understandable and it is still the wrong default: the correct answer is the category the regulation actually specifies, which requires reading it against your change rather than rounding up.

What decides the category

What the change touches. Drug substance manufacturing site, drug product site, specification, analytical method, formulation, container closure, labelling. Each has its own treatment.

Whether the change is supported by data you already have. A site change supported by comparable batch and stability data reads differently to one without.

Whether it affects an established condition. Under ICH Q12, the elements a regulator relies on are identified explicitly, and a change to something outside them is not a reportable change at all.

What FDA has said about changes like it. The guidance documents on post-approval changes are specific, and precedent for a similar change to a similar product is the most useful evidence you can bring.

The part that is easy to miss

The category also tells you what internal work the change requires, which is the part teams discover late.

A change that invalidates a qualification report means new studies. A change to a container closure may require new extractables and leachables data and requalification. Discovering that after choosing the category, rather than while choosing it, is how a CBE-30 becomes a PAS three weeks later.

And if the product is approved in multiple markets, the US category tells you nothing about the rest. Each health authority has its own pathway, and a change that is an annual report item in the United States can be a prior approval variation elsewhere.